In Brief: FDA warning letter grace period
This article was originally published in The Gray Sheet
FDA warning letter grace period: Proposal to give firms a 15-day response period after receiving an FDA-483 inspectional observation form prior to issuing a warning letter is slated for discussion at an April meeting of FDA's Field Committee. The change in policy would obviate issuance of a warning letter if a firm corrected all violations during the grace period ("The Gray Sheet" Dec. 22, I&W-5)...
You may also be interested in...
Women implanted with Bayer’s Essure birth-control device have significantly higher rates of pelvic pain, uterine bleeding and hypersensitivity compared to women who undergo tubal ligation, according to initial results from a government-mandated postmarket study. See what US FDA’s spokeswoman Alison Hunt said about it here.
Companies developing antibiotics to get financial and technical support from more than 20 firms contributing to new AMR Action Fund. Initiative is also pushing for reimbursement reform and other policies to support commercial marketing.
Joe Biden’s presidential campaign now has a plan to address supply chains and encourage US-based manufacturing of prescription drugs. That affirms the unlikely national prominence of the issue – and reduces the chances of meaningful legislation this year.